Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Receivables (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Receivables for 16 consecutive years, with $46.7 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 42.92% to $46.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.7 million through Dec 2025, down 42.92% year-over-year, with the annual reading at $46.7 million for FY2025, 42.92% down from the prior year.
  • Receivables hit $46.7 million in Q4 2025 for Ironwood Pharmaceuticals, down from $120.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $138.0 million in Q4 2021 to a low of $39.8 million in Q1 2025.
  • Historically, Receivables has averaged $101.9 million across 5 years, with a median of $116.1 million in 2022.
  • Biggest five-year swings in Receivables: plummeted 51.18% in 2024 and later surged 58.01% in 2025.
  • Year by year, Receivables stood at $138.0 million in 2021, then fell by 5.8% to $130.0 million in 2022, then dropped by 0.69% to $129.1 million in 2023, then crashed by 36.56% to $81.9 million in 2024, then tumbled by 42.92% to $46.7 million in 2025.
  • Business Quant data shows Receivables for IRWD at $46.7 million in Q4 2025, $120.4 million in Q3 2025, and $86.2 million in Q2 2025.